Health Care · Pharmaceutical Preparations

MIRM Mirum Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1759425129 filings
Russell 2000

MIRM at a glance

Mirum Pharmaceuticals, Inc. (MIRM, SEC CIK 1759425) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Mirum Pharmaceuticals, Inc. (MIRM) shares worth $2.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Ramasastry Saira on November 16, 2026 of 2,000 shares at $92.28 per share.
  • In the last 90 days, MIRM insiders reported 0 open-market purchases ($0) and 8 open-market sales ($7.3M) on Form 4, a net sale of $7.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$521.3M
+54.7% vs prior year
Insiders · 90 days
0 buys · 8 sells
Net −$7.3M
13F holders
29 funds
$2.0B · −1 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core biopharma focused on rare diseases with three approved medicines: Livmarli, Cholbam, Ctexli
  • Acquired asset portfolios in 2023-2026: Travere’s bile acid medicines and Bluejay’s brelovitug for hepatitis D treatment
  • Strategic expansion into chronic HDV with brelovitug advancing in global Phase 3 AZURE program, topline data expected H2 2026
  • Livmarli approved in multiple countries for ALGS and PFIC; pursuing expanded indications with EXPAND Phase 3 study (results Q4 2026)
  • Brelovitug Phase 2 showed 100% virologic response at 48 weeks, granted FDA Breakthrough and EMA PRIME designations

Risk Factors

  • Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law
  • Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals
  • Operational risk integration of Bluejay assets/employees critical to brelovitug development, potential disruption if integration fails
  • Competitive risk several companies including Shionogi and Harmony Biosciences developing therapies for fragile X syndrome
  • Financial risk dependence on key personnel amid fierce competition for talent in Foster City, CA with 369 full-time employees

AI summary of the MIRM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $185.7M, up $52.7M YoY from $133.0M
  • Net loss $40.8M vs $2.9M net income; operating margin -32.2% vs 2.0%
  • Best performer Livmarli: $133.4M, up $41.2M; Bile Acid Medicines $52.3M, up $11.5M
  • Cash, equivalents and investments $500.5M vs $391.4M at December 31, 2025; nine-month operating cash flow -$277.3M
  • Outlook: cash sufficient through at least next 12 months; continued net losses and higher brelovitug development spending expected

Risk Factors

  • New regulatory risk: July 2026 FDA Form 483 cited untimely expedited adverse-event reports by Mirum and its pharmacovigilance vendor
  • Most material update: FDA recommended a Phase 3 volixibat PSC study, delaying the planned NDA submission based on VISTAS data
  • Market-access risk: Medicare negotiation, Most-Favored-Nation pricing proposals and German orphan-drug threshold reduction to €30 million
  • Competitive risk: LIVMARLI generic ANDA filings triggered four 2025 patent complaints and a 2026 tablet litigation
  • Financial risk: nine-month 2026 net loss $898.1 million, accumulated deficit $1.6 billion as continued losses are expected

AI summary of the MIRM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 8.01: Other Events

  • AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment
  • Positive result completes the second Phase 3 study supporting brelovitug’s planned U.S. registration package
Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Mirum announced financial results for the quarter ended September 30, 2026
  • Corporate update released alongside quarterly results

Item EX-99.1: Item EX-99.1

  • Q3 net product sales $185.7M, up from $133.0M, with 2026 guidance raised to $715M-$720M
  • LIVMARLI sales $133.4M, up 45% year over year, while Bile Acid Medicines sales reached $52.3M, up 28%
Filed Oct 26, 2026Full analysis →

Item 8.01: Other Events

  • Positive Cohort 2 results in 25 children support expanding ATEBRIOZ approval to ages 6 to <12
  • HO lesion volume fell 8.09 cm³ with zilurgisertib versus a 9.14 cm³ increase with placebo, nominal p=0.003

AI summaries of MIRM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MIRM

Don't miss the next MIRM filing

  • Alerts as it files. A push when MIRM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MIRM, by share count.
  • Ask anything. An AI agent that reads every MIRM filing and answers with sources.

MIRM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Ramasastry SairaSellNov 16, 2026$92.28
Ramasastry SairaMNov 16, 2026-
Ramasastry SairaMNov 16, 2026$28.97
Brege LauraSellNov 11, 2026$94.05
Brege LauraMNov 11, 2026$16.71
Brege LauraMNov 11, 2026-
Brege LauraSellNov 11, 2026$94.74
Peetz ChristopherSellNov 4, 2026$90.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$336.9M$521.3M
Operating Income--$87.6M-$22.1M
Net Income-$163.4M-$87.9M-$23.4M
Op. Margin--26.0%-4.2%
Net Margin--26.1%-4.5%
Balance Sheet
Total Assets-$670.8M$842.8M
Equity$248.7M$225.6M$314.7M
ROE-65.7%-39.0%-7.4%
Per Share
EPS$-4.00$-1.85$-0.47
Cash Flow
Operating CF-$10.3M$55.8M
CapEx$109K$993K$954K

Source: XBRL data in Mirum Pharmaceuticals, Inc. (MIRM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MIRM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MIRM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$2.01B
Q2 202630$2.96B
Q1 202631$1.94B
Q4 202526$1.36B
Q3 202528$1.22B
Q2 202527$818.9M
Q1 202524$486.8M
Q4 202419$339.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 214 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MIRM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 17, 2026--
4Nov 13, 2026--
8-KNov 10, 2026Analysis-
4Nov 4, 2026--
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
8-KOct 26, 2026Analysis-
4Oct 19, 2026--
4Oct 14, 2026--
8-KOct 13, 2026Analysis-
4Oct 6, 2026--
8-KSep 28, 2026Analysis-
4Sep 15, 2026--
8-KSep 8, 2026Analysis-
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 19, 2026--
4Aug 12, 2026--
4Aug 11, 2026--
SC 13GAug 6, 2026-
4Aug 5, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
4Jul 8, 2026--
4Jul 8, 2026--

Related Health Care companies

All Health Care →

MIRM SEC filings: frequently asked questions

Are MIRM insiders buying or selling?

In the last 90 days, Mirum Pharmaceuticals, Inc. (MIRM) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $7.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MIRM stock?

As of September 30, 2026, the largest Mirum Pharmaceuticals, Inc. (MIRM) holders among the 13F filers tracked by SignalX were BlackRock ($403.7 million), Vanguard Portfolio Management LLC ($225.1 million), T. Rowe Price Group ($217.5 million), Vanguard Capital Management LLC ($213.6 million), State Street Corp ($204.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MIRM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47. The figures come from the XBRL data in the 10-K.

What are the main risks in MIRM's latest 10-K?

In the 10-K filed February 25, 2026, Mirum Pharmaceuticals, Inc. (MIRM) flagged: Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law. Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals. (AI summary of the Risk Factors section.)

What did MIRM report in its latest 8-K?

Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K on November 10, 2026 reporting Item 8.01 (Other Events). AZURE-4 met its Week 24 primary endpoint: 59% at 300 mg QW and 44% at 900 mg Q4W versus 0% delayed treatment.

What are the latest MIRM SEC filings?

Mirum Pharmaceuticals, Inc. (MIRM) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 17, 2026.

What is MIRM's SEC CIK number?

Mirum Pharmaceuticals, Inc. (MIRM)'s SEC Central Index Key (CIK) is 1759425. EDGAR lists every MIRM filing under that number.

Ask anything about MIRM

The research agent reads MIRM's filings, financials, insider trades and 13F holders, then answers with sources.